VPC
TVTX icon

Vestal Point Capital’s Travere Therapeutics TVTX Stock Holding History

Vestal Point Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-355,000
Closed -$5.25M – 93
2025
Q2 		$5.25M Buy
+355,000
New +$5.88M 0.28% 51

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vestal Point Capital's TVTX Position: Q3 2025 in Review

Vestal Point Capital sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 355,000 shares — an estimated $5.25M sold.

Vestal Point Capital first reported a position in TVTX in Q2 2025 and held it in 1 quarter. The position peaked at $5.25M in Q2 2025. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

  • Vestal Point Capital reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Vestal Point Capital sold 355,000 Travere Therapeutics shares in Q3 2025, an estimated $5.25M.
  • Vestal Point Capital first reported a position in Travere Therapeutics in Q2 2025 and held it in 1 quarter.
  • Vestal Point Capital's Travere Therapeutics position peaked at $5.25M in Q2 2025.
  • 238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.